Epstein-Barr Virus and Cancer.

@article{Farrell2019EpsteinBarrVA,
  title={Epstein-Barr Virus and Cancer.},
  author={Paul J. Farrell},
  journal={Annual review of pathology},
  year={2019},
  volume={14},
  pages={
          29-53
        }
}
  • P. Farrell
  • Published 24 January 2019
  • Biology, Medicine
  • Annual review of pathology
Epstein-Barr virus (EBV) contributes to about 1.5% of all cases of human cancer worldwide, and viral genes are expressed in the malignant cells. EBV also very efficiently causes the proliferation of infected human B lymphocytes. The functions of the viral proteins and small RNAs that may contribute to EBV-associated cancers are becoming increasingly clear, and a broader understanding of the sequence variation of the virus genome has helped to interpret their roles. The improved understanding of… 
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
TLDR
The inclusion of gH/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development, and has the potential to increase the efficacy of a therapeutic EBV vaccine.
MicroRNA and Other Non-Coding RNAs in Epstein–Barr Virus-Associated Cancers
TLDR
EBV-encoded microRNAs and ncRNAs are discussed and how their detection could aid in the diagnosis, prognostication, and monitoring of treatment in patients with EBV-associated malignancies are considered.
Modification of EBV-Associated Pathologies and Immune Control by Coinfections
  • C. Münz
  • Medicine, Biology
    Frontiers in Oncology
  • 2021
TLDR
The underlying mechanisms reveal new aspects of EBV-associated pathologies and point toward treatment possibilities for their prevention by the human immune system.
Epstein-Barr Virus Infection in the Development of Neurological Disorders.
Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
  • C. Münz
  • Biology
    Nature Reviews Microbiology
  • 2019
TLDR
The evidence for EBV persistence without B cell transformation and the role of early abortive lytic replication as well as non-coding RNAs in EBV-driven tumorigenesis is discussed.
Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases
TLDR
EBV infection of cord blood T cells by highly characterized, cloned EBV genomes is demonstrated and it is suggested that transient infection of T cells may be part of normal asymptomatic infection by EBV in young children.
Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases
TLDR
The type 1/type 2 classification of EBV remains the major form of variation and is defined mostly by EBNA2 and EBNA3, but the type 2 single-nucleotide polymorphisms at theEBNA3 locus extend into the adjacent gp350 and gp42 genes, whose products mediate infection of B cells by EBV.
Do Epstein–Barr Virus Mutations and Natural Genome Sequence Variations Contribute to Disease?
TLDR
If some EBV strains prove to be more pathogenic than others, this suggests the possible value of immunising people against infection by those pathogenic strains.
Progress in EBV Vaccines
TLDR
The ability of next generation vaccines to safeguard against B-cell and epithelial cell infection, as well as to target infected cells during all phases of infection, is likely to decrease the negative impact of EBV infection on the human population.
Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis
TLDR
EBV specific TCR transgenic T cells constitute a promising therapeutic strategy against EBV associated malignancies and might be protective for the control of EBV infection and associated oncogenesis.
...
...